OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close […]
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40 […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that it has raised $27 million in a Series C financing with […]
Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients […]
In order to face growing market demand for quality probiotic food supplements, Lallemand Health Solutions is investing in a brand new bacterial production plant in Mirabel, Canada. Using state-of-the-art equipment and production process, the new […]
Trace Genomics®, a San Francisco Bay area startup developing revolutionary, AI-enabled diagnostic tools for farmers to increase yields and reduce costs, has closed a $13 million Series A round. Trace Genomics has launched the first […]
Microbiotica, a leading player in microbiome-based therapeutics, announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised […]
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company […]
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), […]
Eagle Genomics announce partnership with Microsoft Genomics, a Microsoft Azure service dedicated to meeting the computational challenges of the genomics era. This is the first Microsoft partner focused in the microbiome genomics market. Microbiomics is […]
Synthetic Biologics, Inc. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today the […]